Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELAGOLIX vs ANDROID 10
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Gonadotropin-releasing hormone (Gn RH) receptor antagonist that competitively binds to Gn RH receptors in the anterior pituitary, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, thereby suppressing ovarian estradiol production.
Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.
Management of moderate to severe pain associated with endometriosis
Male hypogonadism (primary and hypogonadotropic),Delayed puberty in males,Off-label: Androgen replacement in transgender men (masculinizing hormone therapy)
200 mg orally twice daily
Testosterone undecanoate 750 mg (3 m L) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.
Terminal elimination half-life is approximately 4–6 hours. Clinical context: Steady state achieved within 5 days; tid dosing maintains therapeutic concentrations.
8 hours; clinical context: steady-state achieved in 2-3 days, dosing interval 8-12 hours.
Primarily metabolized by CYP3A4; minor contribution from CYP2D6 and CYP2C8.
Hepatic metabolism via CYP3A4; undergoes extensive first-pass metabolism; metabolites primarily excreted renally.
Renal (approximately 70% as unchanged drug and metabolites), fecal (approximately 30%)
Renal: 90% as glucuronide and sulfate conjugates, 6% as unchanged drug; fecal: 4%.
Approximately 99% bound to albumin and alpha-1-acid glycoprotein
97-99% bound primarily to sex hormone-binding globulin (SHBG) and albumin.
Vd/F is approximately 40–60 L (0.5–0.8 L/kg). Clinical meaning: Extensive tissue distribution, consistent with a large volume of distribution.
0.5-1.0 L/kg; indicates extensive distribution into tissues and organs.
Oral: Approximately 30% (low due to first-pass metabolism); food increases exposure by approximately 30%.
Oral: low (variable, ~5-20% due to first-pass metabolism); intramuscular: 100%.
e GFR 30-89 m L/min: no adjustment. e GFR 15-29 m L/min: 100 mg twice daily. e GFR <15 m L/min: not recommended.
No specific dose adjustment required for renal impairment; monitor serum testosterone levels and clinical response. For severe renal impairment (GFR <30 m L/min), consider increased monitoring due to potential fluid retention.
Child-Pugh A: no adjustment. Child-Pugh B: 100 mg twice daily. Child-Pugh C: not recommended.
Contraindicated in patients with severe hepatic dysfunction (Child-Pugh class C). For mild to moderate impairment (Child-Pugh class A or B), use with caution and consider dose reduction; monitor liver function tests regularly.
Not established; safety and efficacy in pediatric patients have not been studied.
Not recommended for use in children; safety and efficacy not established. For delayed puberty in adolescent males: testosterone enanthate 50-200 mg intramuscularly every 2-4 weeks, titrated to response, with monitoring of bone age.
No specific dose adjustment required; clinical studies included limited patients ≥65 years, but no differences in safety or efficacy observed.
Start at low end of dosing range (e.g., testosterone cypionate 50 mg intramuscularly every 4 weeks or gel 25 mg daily) due to potential increased sensitivity and risk of prostatic hypertrophy or cardiovascular events. Monitor serum testosterone, hematocrit, and prostate-specific antigen (PSA).
None
None
Hepatic transaminase elevations: monitor liver function before and during treatment; discontinue if elevation >3x ULN or if signs of liver injury occur.,Bone density loss: monitor bone mineral density with long-term use; consider additional calcium/vitamin D.,Mood changes: increased risk of depression, suicidal ideation; monitor for new or worsening symptoms.,Altered menstrual bleeding; exclude pregnancy before starting.,Risk of osteoporosis with prolonged use.
Risk of hepatotoxicity; use with caution in patients with liver disease. Monitor liver function, lipid profile, and prostate-specific antigen (PSA). May cause fluid retention, gynecomastia, priapism, and sleep apnea. Not for use in women who are pregnant or breastfeeding. May accelerate growth of prostate cancer and benign prostatic hyperplasia. Androgenic effects may cause virilization in women.
Known hypersensitivity to elagolix or any excipients,Concomitant use with strong organic anion-transporting polypeptide (OATP) 1B1 inhibitors (e.g., cyclosporine, gemfibrozil),Pregnancy, or women of reproductive potential not using effective contraception,Existing osteoporosis or severe bone loss,History of suicidal ideation or behavior
Men with carcinoma of the prostate or breast; history of hypersensitivity to testosterone or any component; women who are pregnant or may become pregnant (risk of fetal harm); patients with severe hepatic or cardiac disease.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and may increase elagolix levels. No other food restrictions.
No known food interactions. However, methyltestosterone can increase appetite and cause weight gain; a balanced diet is recommended.
First trimester: High risk of pregnancy loss and major birth defects based on animal data and mechanism of action. Second and third trimesters: Contraindicated due to potential for harm. Elagolix is contraindicated in pregnancy.
Android 10 is a combination of methyltestosterone and ethinyl estradiol. Methyltestosterone is an androgen; exposure during pregnancy, particularly during the first trimester, can cause virilization of the female fetus. Ethinyl estradiol is contraindicated in pregnancy due to risk of fetal harm. Use is contraindicated in all trimesters.
Elagolix is excreted in animal milk; no human data. M/P ratio unknown. Not recommended during breastfeeding.
Methyltestosterone and ethinyl estradiol are excreted in breast milk. Methyltestosterone may cause virilization in female infants. Ethinyl estradiol may reduce milk production and quality. M/P ratio not available. Breastfeeding is contraindicated.
No dose adjustments studied; contraindicated in pregnancy. No data on PK changes requiring dose modification.
Contraindicated in pregnancy; no dosing adjustments apply. If inadvertent use occurs, discontinue immediately.
Elagolix is an oral Gn RH antagonist for endometriosis-associated pain. Monitor bone mineral density (BMD) with dual-energy X-ray absorptiometry (DXA) if using >12 months or in patients with osteoporosis risk. Avoid use with strong CYP3A inducers (e.g., rifampin) or inhibitors (e.g., ketoconazole). May reduce efficacy of hormonal contraceptives. Assess pregnancy status before starting due to teratogenicity.
Android 10 is a brand name for methyltestosterone, an androgen and anabolic steroid. Use is restricted to replacement therapy in males with hypogonadism or delayed puberty due to androgen deficiency. Monitor liver function due to risk of peliosis hepatis and hepatocellular carcinoma. Contraindicated in males with breast or prostate cancer. Can cause erythrocytosis; monitor hematocrit. Discontinue if signs of virilization in women or priapism in men. Use caution in elderly due to increased risk of prostatic hypertrophy.
Take elagolix at the same time daily with or without food.,Avoid grapefruit or grapefruit juice during treatment.,Use non-hormonal contraception (e.g., condoms) because elagolix may reduce hormonal contraceptive effectiveness.,Report severe headaches, vision changes, or heavy bleeding promptly.,Do not take elagolix if pregnant or planning to become pregnant; use effective birth control.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Report signs of liver problems: yellowing of skin or eyes, dark urine, light-colored stools, abdominal pain.,Notify your doctor if you experience swelling of ankles or feet, trouble breathing, or persistent erections lasting more than 4 hours.,May cause aggressive behavior, mood swings, or depression; contact your doctor if these occur.,Do not take if you are pregnant or breastfeeding.,Keep all appointments for blood tests and liver function monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ELAGOLIX vs ANDROID 10, answered by our medical review team.
ELAGOLIX is a Gonadotropin-Releasing Hormone Antagonist that works by Gonadotropin-releasing hormone (Gn RH) receptor antagonist that competitively binds to Gn RH receptors in the anterior pituitary, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, thereby suppressing ovarian estradiol production.. ANDROID 10 is a Androgen that works by Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELAGOLIX and ANDROID 10 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELAGOLIX is: 200 mg orally twice daily. The standard adult dose of ANDROID 10 is: Testosterone undecanoate 750 mg (3 m L) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELAGOLIX and ANDROID 10 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELAGOLIX is classified as Category C. First trimester: High risk of pregnancy loss and major birth defects based on animal data and mechanism of action. Second and third trimesters: Contraindicated due to potential for. ANDROID 10 is classified as Category C. Android 10 is a combination of methyltestosterone and ethinyl estradiol. Methyltestosterone is an androgen; exposure during pregnancy, particularly during the first trimester, can . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.